BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24217786)

  • 1. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
    Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
    Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
    Chung HH; Kwon HW; Kang KW; Park NH; Song YS; Chung JK; Kang SB; Kim JW
    Ann Surg Oncol; 2012 Jun; 19(6):1966-72. PubMed ID: 22124757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
    Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.
    Papadia A; Bellati F; Ditto A; Bogani G; Gasparri ML; Di Donato V; Martinelli F; Lorusso D; Benedetti-Panici P; Raspagliesi F
    Ann Surg Oncol; 2015 Dec; 22(13):4204-10. PubMed ID: 25777095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
    Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P
    Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
    Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
    Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
    Huang LP; Yu YH; Sheng C; Wang SH
    Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
    Zang RY; Harter P; Chi DS; Sehouli J; Jiang R; Tropé CG; Ayhan A; Cormio G; Xing Y; Wollschlaeger KM; Braicu EI; Rabbitt CA; Oksefjell H; Tian WJ; Fotopoulou C; Pfisterer J; du Bois A; Berek JS
    Br J Cancer; 2011 Sep; 105(7):890-6. PubMed ID: 21878937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
    Lorusso D; Ratti M; Ditto A; Raspagliesi F
    Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H; Pradjatmo H
    Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.